Loading…
Loading…
KCPC does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KCPC and 80,000+ other tickers.
See exactly how KCPC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KCPC and 80,000+ other tickers.
Key Capital Corporation (KCPC), an emerging enterprise, operates globally in both the mineral extraction sector and the provision of financial services to the mining industry. The company offers capital to mining ventures through a variety of strategies, including streaming agreements, structured financing, and direct equity investments. These arrangements typically grant KCPC an interest in the future output from mines yielding precious metals such as gold and silver, base metals, or various energy products. Beyond this, KCPC also allocates funds to a wider range of resource and energy…
MaxCellLife 24/7 Immune Supplement has been Reported Effective for COVID-19, Colds and Flu, with 90% Reduction in COVID-19 Virus Infectivity Additionally Reported Through Independent University Research Lab Study NEW YORK, NY / ACCESSWIRE / April 29, 2021 / KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises it is evident the COVID situation in India is a humanitarian catastrophe, and that although the head of WHO states it is "beyond heartbreaking", it appears that the COVID crisis in India will unfortunately get a lot worse. A major factor impacting India is that, with its resources stretched and its hospitals overrun, there is no viable affordable therapeutic product available to the millions of people with COVID-19 infection.
90% Reduction in COVID-19 Virus Infectivity Reported Through Independent University Research Study NEW YORK, NY / ACCESSWIRE / April 26, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections. Originally developed some 10 years ago as a patented oral pill vaccine to support strong immunity, as this is the obvious natural defense to catching colds and/or viral infections, HAP-V+ is today increasingly being used in countries where it is currently available in cases of COVID-19.
MaxCellLife MIND, a Proprietary M.Vaccae and Magnesium Compound, targets the Multi-Billion Anxiety, Stress and Depression Market NEW YORK, NY / ACCESSWIRE / April 8, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor (Thailand) Co., Ltd, the Company is today launching its unique M.vaccae and magnesium dietary supplement in the $18 billion Anxiety and Stress market. MaxCellLife MIND is now available through the Company's marketing website https://MaxCellLife.com.
Jennifer Reilly appointed Marketing Director to Lead MaxCellLife.com Launch NEW YORK, NY / ACCESSWIRE / April 7, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the Company is launching https://MaxCellLife.com today specializing in the sales and marketing of science driven supplement and skincare products. The Company Chairman's partner, Ms Jennifer Reilly, has been appointed the Key Capital Marketing Director and will lead the MaxCellLife.com launch and the sales and marketing team.
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarify the Company's corporate focus, direction, and progress. Also, for the public to better understand the Company, its mission, and its opportunity.